We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

1st Circuit Panel Upholds Dismissal Of Sarepta Securities Class Action

Mealey's (April 5, 2018, 2:04 PM EDT) -- BOSTON — Shareholders have not shown that pharmaceutical company Sarepta Therapeutics Inc. and three of its senior executives materially misrepresented investors that a 2014 new drug application (NDA) with the U.S....
To view the full article, register now.